Cholesterol gets a new name: from public enemy to dyslipidemia

American guidelines rebrand cholesterol as dyslipidemia

Forty years of blaming the egg, butter and LDL for cardiovascular disease. And now the reference manual changes its title: it is no longer called blood cholesterol, but dyslipidemia. The change is not cosmetic. When an institution renames its founding document, it is usually because the word at the top carries baggage that is hard to defend in public.

Why the cholesterol guidelines are now called dyslipidemia guidelines

The rebranding comes with documentation: Revista Española de Cardiología and the American Heart Association's professional website are cited as the sources behind the shift. The harshest reading of the matter holds that the term has become toxic and that the new name preserves the framework —the altered marker as a threat— without carrying four decades of claims that no longer hold up as they once did.

There is debate over the intent. One camp reads it as simple clinical precision: dyslipidemia better describes a set of alterations, not just cholesterol. Another responds that this is precisely what has been argued for years and that the institution is merely catching up with a conversation that had already left it behind.

Statins, coenzyme Q10 and the business of overmedication

The figure driving the debate is stark: 93 million people take statins in the United States. The argument gaining most traction points to a little-publicized effect: statins do not only block cholesterol production, they also block coenzyme Q10, the compound mitochondria need to produce energy in the heart and muscles. The full quote and its source are one click away, and it is worth reading in full before taking it at face value.

In parallel, a critical body of literature is emerging as a shared reference: "Crónica de una sociedad intoxicada" (Chronicle of an Intoxicated Society) by Joan Ramon Laporte, and the Danish author Peter Gøtzsche's books on the overmedicated world. This is not self-help material: these are volumes on pharmacology and public health, which explains why they circulate so widely among readers who distrust the patient leaflet.

The next marker: ferritin

The shifting focus already has a candidate. Ferritin is starting to appear linked to cancer and a broad catalogue of ailments in annual medical check-ups, opening a new front for those who undergo periodic blood tests as a job requirement. From cholesterol to ferritin: the pattern repeats itself, and the pattern is always the same — a number that shows up in the test and a pill that appears behind it.

---

The shift in focus —from fat to iron, from the pill to the mandatory check-up— leaves a practical question unanswered. Millions of people alter their prescribed regimens on their own, sometimes at half the dose, without consulting anyone. How many will go back to ask their doctor, and how many will never set foot in the clinic again?